Low first-phase left ventricular ejection fraction was not associated with increased 1-year all-cause mortality (8.3% vs 9.2%; P=0.773) compared to high LVEF1 in patients undergoing TAVI.
Cohort
Does low LVEF1 predict adverse clinical outcomes in patients undergoing TAVI for symptomatic severe AS with preserved LVEF?
Reduced first-phase left ventricular ejection fraction (LVEF1) is not associated with adverse clinical outcomes at 1 year following TAVI in patients with symptomatic severe aortic stenosis and preserved LVEF.
Absolute Event Rate: 8.3% vs 9.2%
p-value: p=0.773
BACKGROUND: First-phase left ventricular ejection fraction (LVEF1) is an early marker of left ventricular remodeling. Reduced LVEF1 has been associated with adverse prognosis in patients with aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF). It remains to be determined, whether reduced LVEF1 differentiates clinical outcomes after aortic valve replacement. OBJECTIVES: We investigated the impact of LVEF1 on clinical outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) for symptomatic severe AS with preserved LVEF (≥ 50%). METHODS: In the prospective Bern TAVI registry, we retrospectively categorized patients according to LVEF1 as assessed by transthoracic echocardiography. Clinical outcomes of interest were all-cause mortality and residual heart failure symptoms (New York Heart Association (NYHA) functional class III or IV) at 1 year after TAVI. RESULTS: ; P = 0.027) compared to patients with high LVEF1. At 1 year, the incidence of all-cause/cardiovascular death, and NYHA III or IV were comparable between patients with low and high LVEF1 (8.3% vs. 9.2%; P = 0.773, 3.9% vs. 6.0%; P = 0.276, 12.9% vs. 12.2%; P = 0.892, respectively). CONCLUSIONS: Reduced LVEF1 was not associated with adverse clinical outcomes following TAVI in patients with symptomatic severe AS with preserved LVEF. CLINICAL TRIAL REGISTRATION: https://www. CLINICALTRIALS: gov. NCT01368250.
Tomii et al. (Sat,) conducted a cohort in Symptomatic severe aortic stenosis with preserved LVEF. Low first-phase left ventricular ejection fraction (LVEF1) vs. High LVEF1 was evaluated on All-cause death (p=0.773). Low first-phase left ventricular ejection fraction was not associated with increased 1-year all-cause mortality (8.3% vs 9.2%; P=0.773) compared to high LVEF1 in patients undergoing TAVI.